RespireRx Pharmaceuticals Inc (CE) (RSPI) News

More press mentions RespireRx Pharmaceuticals, in particular the relevance to spinal cord neuroplasticity, which is, by the way the reason why Dr. Dariusz Nasiek joined the board of director, and provided 100000$ in cash, which he arranged to be backed by 33 million shares of RSPI as a disincentive to further dilution.

And in addition, we should bear in mind that the DoD clinical trial funding is specifically about using the new ampakine CX1739 to support therapeutic hypoxia for recovery of spinal cord damage.

So the pieces of the puzzle are coming together. I would not be surprised to get an update soon on how the setting up of the trial is unfolding, recruiting of subjects, etc.

I posted here earlier this year the name of the Dr who will run the trial, and where. I also confirmed with him that this was indeed underway. Let me try to get in touch with him again.

https://www.einnews.com/pr_news/773474888/spinal-cord-injury-therapeutics-market-projected-to-witness-substantial-growth-2024-2031-abbvie-inc-pfizer-inc

https://southeast.newschannelnebraska.com/story/52104007/spinal-cord-injury-therapeutics-market-projected-to-witness-substantial-growth-2024-2031-abbvie-inc-pfizer-inc

Maybe they just get funding deal and go straight to Nasdaq?? Have seen mergers before with a company with cash looking for development assets. Could this be the reason for the non chalant approach the past 6 months??

I mean they think the OSA program is worth 20-40 million. The phase 2 candidate is worth a chunk certainly and KRM-ll-81 with a robust set of successful preclinicals might be more valuable than all the rest combined…

Many think this is worth a nickel or two now in anticipation of multiple clinical trials forthcoming..

So when it shows 75000 reads in a day that is coming from 3 of us permabulls who do a shit ton of due diligence and expecting company executives to meet their fiduciary duties?

And this is similar daily for months on end…. Uh huh.

I agree and they need to get this resolved asap!

Position on the BOB is based on "the change in posting activity in the past 24 hours vs. the average from the prior 7 days", not the number of board reads.
On a board like this just a few posters can have a big influence on a BOB position. For example you and 2 other posters account for more than half of the most recent poster activity, making up the majority of what you refer to as "so much interest in this EM stock".

I think it is board reads…

But why so much interest in this EM stock?

Continually..

Tell him all of it. The Break out board measures posting activity and has zero to do with the Company's operations.

Sadly the more time that goes by they will never get currant. Still makes no sense they didn't file.

Break out board

Bob? What's that? 

Imagine what it will be like if they ever go current again?

Then through in an FDA Approval and or institutional partnerships we could all be celebrating here.

Look at that, RSPI in back on the BoB, not bad for a ticker in the EM!

Some people like the paint color green, some like the paint color red.

I doubt there is any or will be any effort to revive older ampakine compounds. They have already focused soley on the low impact ampakines and have this phase 2 for SCI funded and supposedly I think a presentation a few years back suggested they needed just funding to get CX-1739 or CX717 in ADHD phase 2 clinicals. I am guessing there is way too much risk and stigma with the old high impact compounds. Plus they have an enormously promising gabakine and an OSA program with patent position that both are and can be extremely valuable. Focus and updates need to be centered around these compounds heading into clinicals.

Now maybe in the future they can afford to explore the past with newer technology, but given the current lack of everything seems far fetched to even place into ones imagination...

Why would anyone sell RSPI stock while it is in EM status to profit such small amount of money?

LT - CX9292, a high impact ampakine with short half-life, was shown it can be administered orally by drinking water and was shown to be effective in mice. Are there others? Am I being biased in my holy grail assessment of RSPI impact on neuropharmacology? Lippa also is (was?) head of venture capital firms - is there financing that we don't know about? Is RSPI quietly accumulating their stock at ridiculous prices? Then there is that PhD thesis online where the author complained that he could not publish his results on CX929 until 2026 (the thesis is no longer available). Does that mean for the university researchers have to sign nondisclosures to gain access to the ampakines for research? They only can publish when given permission? So many questions - will January finally give us the answers?

Maybe, but I don't see RSPI having any involvement. They can't even get the basic business entity activities accomplished and have zero bandwidth to attempt to create targeting ampa compounds as they have enough on their plate now that doesnt appear to be moving. Their ampakine focus for the next how many years can only be on the low impact compounds with the DOD phase 2 SCI trial and how that may lead into ADHD trials. Let alone needing to dedicate resources to the OSA and gabakine programs which may be much more valuable with larger market reach anyhow.

Possibly nanoparticles can revive past high-impact ampakines, but I am guessing that ship has long sailed here with no patent rights any further on those long lost compounds. Now maybe.... if they acted like a legit mid major pharma and sustained valuations representitive of their progress into clinical trials on 3 seperate platforms they could then have the flexibility to acquire the people resources, the collaborative resources and smallish funding necessary to pursue an ampakine revival and expansion of that platform.... But as the months tick by, they appear to have zero desire in this regards.

I see your points, and the possibility if new technology can mitigate past ampakine concerns and revive development, but do you think the company sees any of it or has any desire to go down those paths?

Market research report from Coherent Market Insights mentions RespireRx:

Spinal Cord Injury Therapeutics Market Projected To Witness Substantial Growth, 2024-2031:

Key Players Covered In This Report:

Teva Pharmaceutical Industries Ltd.
AbbVie Inc
Pfizer Inc.
Reddy's Laboratories Ltd
Zydus Cadila
ReNetX Bio, Inc
InVivo Therapeutics Holdings
Lineage Cell Therapeutics, Inc
Kringle Pharma Inc.
Acorda Therapeutics Inc.
Bioaxone Biosciences, Inc
RespireRx Pharmaceuticals Inc.
NervGen
Rising Pharmaceuticals, Inc
ScieGen Pharmaceuticals, Inc
MSN Laboratories Private Limited
Lannett Co Inc.


https://menafn.com/1109048318/Spinal-Cord-Injury-Therapeutics-Market-Projected-To-Witness-Substantial-Growth-2024-2031-Abbvie-Inc-Pfizer-Inc

Another indication for ampakine research?

Small-molecule targeting AMPA-mediated excitotoxicity has therapeutic effects in mouse models for multiple sclerosis

Dongxu Zhai, Shuxin Yan, James Samsom, Le Wang, Ping Su, Anlong Jiang, Haorui Zhang, Zhengping Jia Izhar Wallach, Abraham Heifets, Chiara Zanato, Chih-Chung Tseng, Albert H C Wong, Iain R Greig, Fang Liu
Affiliations Expand
PMID: 38064562 PMCID: PMC10708182 DOI: 10.1126/sciadv.adj6187
Sci Adv. 2023 Dec 8;9(49):eadj6187.
Epub 2023 Dec 8.
Abstract
While most research and treatments for multiple sclerosis (MS) focus on autoimmune reactions causing demyelination, it is possible that neurodegeneration precedes the autoimmune response. Hence, glutamate receptor antagonists preventing excitotoxicity showed promise in MS animal models, though blocking glutamate signaling prevents critical neuronal functions. This study reports the discovery of a small molecule that prevents AMPA-mediated excitotoxicity by targeting an allosteric binding site. A machine learning approach was used to screen for small molecules targeting the AMPA receptor GluA2 subunit. The lead candidate has potent effects in restoring neurological function and myelination while reducing the immune response in experimental autoimmune encephalitis and cuprizone MS mouse models without affecting basal neurotransmission or learning and memory. These findings facilitate development of a treatment for MS with a different mechanism of action than current immune modulatory drugs and avoids important off-target effects of glutamate receptor antagonists. This class of MS therapeutics could be useful as an alternative or complementary treatment to existing therapies.

Yeah, versus a grotesquely deflated valuation that costs added debt, dilution and stagnates opportunities, limits flexibility, etc.

Brilliant strategy.

What do they think fair valuation is? Surely more than the independent valuation of the OSA program considering the gabakine has the premier look exiting preclinicals and DOD funding the other platform.

They are weary of the market getting too excited, and creating grotesquely inflated hype. They seek a path to steady sustainable appreciation of the share price.

You would think listing correct management and BOD would be important!

And all 3 platforms have way outdated information!

It is illogical to cry about lack of funding and otc liquidity when you present the company like a 6th grade science project..

Yet executives, BOD, institutional have all lined up behind equity positions here last few years!! What does that tell you coupled with the lack of desire to parlay a significant DOD funded phase 2 into investor interest!!

I agree that the current state of the website is quite awful. Not only does it look amateurish, on the company management page it lists Dr. James Manuso as the CEO. He left the company on September 30, 2018.

https://www.respirerx.com/corporate/management.html

https://www.globenewswire.com/news-release/2018/06/19/1526825/0/en/RespireRx-Pharmaceuticals-Inc-Announces-Resignation-of-Dr-James-S-Manuso.html

Why did someone sell at this level to drop the pps?

That would be a start! They need an updated website to clearly highlight the asset platforms, current progress, market potential, expected milestones, etc.

An obviously they need off this EM market to bring liquidity and interest back that is essential to capitalize on opportunities to gain talent resources, collaborations and position the assets for next steps so if BP joins the picture they can maximize their position.

bottomline convey a strategy and execute it. fiduciary duty should be a proud endeavor not whatever the current status has been

Great job he needs to know we are gonna hold him to his word!

Just wrote Jeff asking if anything new that could be reported and if he was still working on shareholders news letter. We will see what happens

I recall some poster stating the company chose to "pause" the entire filing process after beginning it and getting most of the way done I think was suggested.

Maybe the company saw further progress on KRM-ll-81 was going to wait for NIH grant status in Q1 2025 and the DOD funded SCI phase 2 was likely to be pushed into 2025 as well versus EOY 2024. IF the OSA program is stalled awaiting results of this phase 1/phase 2 clinical UIC is conducting that may indicate a change of approach with OSA and hence the year long silence on that program. Silence on the EM may have been advantageous in some regard.

The ingredients are there and setting up for a very active and special 2025 as they are on the cusp of clinical trials on all 3 platforms. I hope they get some leadership help as there is no reason these assets should be valued as such. Even at a nickel and 50 million valuation seems really cheap having 3 platforms heading to clinicals where the preclincal efforts have been substaintial and successful to improve odds of success in clincals. I'm optimistic a new year will be transformative from all angles. GLTA.

"AI overview" via Google... Interesting, but could find no articles...AI overreach? But if not could be really huge!

Ampakines are drug candidates that may be useful in treating multiple sclerosis (MS) because they can modulate AMPA-type glutamate receptors (AMPARs):
AMPARs and MS
Glutamate excitotoxicity, mediated by AMPARs, can damage neurons and oligodendrocytes, which are cells that produce myelin in the central nervous system (CNS). In MS, activated immune cells release large amounts of glutamate, which can contribute to lesions.
Ampakines and AMPARs
Ampakines are positive allosteric modulators of AMPARs. They can increase cytosolic calcium levels in astrocytes, which may be sensitive to modulation by ampakines.
Ampakines as a treatment
Small-molecule antagonists of AMPA-mediated excitotoxicity may be a promising treatment for MS. These antagonists could be an alternative or complementary treatment to current immune modulatory drugs.
Glutamate homeostasis
Glutamatergic homeostasis is important for normal physiological processes. Treatment strategies that regulate glutamate homeostasis may benefit MS patients

Maybe. 8 bucks at a time while the company wastes significant time waiting for ??? To communicate and present to stakeholders and potential resources, collaborators, talent and partners?

Someone who understands the extraordinary potential, has access to EM, and wants to keep the price super low in order to accumulate more at a ridiculous price befoe RSPI explodes?

Yep. Many feel exactly the same and wondering WTF?

The company touted their exceptional SEC reporting history for years. Knew they were in line for DOD funding phase 2. They can’t hide their excitement for preclinical darling KRM-II-81 and NIH grant possibilities. And the OSA program has competitors advancing on less and RSPi’s dronabinol licensor UIC in an upcoming phase 1/2 with VA sponsorship!!

So what does it mean that they went radio silent??? IMO big time money is at the door…

Highly desirable assets is what they have presented to investors in the past! Their 3 asset platforms are only better positioned and more valuable today! Those whom invested are glad to own a piece of these assets despite it all…

Hence why this expert market is really a joke.

Who benefits from a last minute reset of the price as such on an $8 trade??

Inexcusable to end the year still on EM after half of 2024 spent there and with zero communication to shareholders. 

Hey Jeff, you're a public fking company, start acting like it. You have a fiduciary duty to shareholders. 

Said it before and I'll say it again, even the corrupt scamming clowns over at ENZC managed to keep a small bio pink current. 

Curious last trade of the year. Is this an effort to keep the price ridiculously low?

May we all prosper in the New Year which I suspect will be augmented by RSPI.

Hopefully we wake up tomorrow to the eoy share holder letter that has been swirling around

Thank you, LTListener. Happy New Year to you as well!

Happy New Year to all.

Wishing all the best of health and happiness in the new year. And just maybe, the powers at be here will turn the page and bring these premier assets to new heights in clinical trials in 2025.

The CEO of OTCMarkets provided an update to that March of 2021 article in September of 2023:
https://blog.otcmarkets.com/2023/09/14/the-expert-market-its-larger-role-post-rule-15c2-11/

https://blog.otcmarkets.com/2021/03/25/understanding-the-expert-market/

It's simple really:
OTC Markets Group operates the Expert Market.
Quotations in Expert Market securities are restricted from public viewing.
Only broker-dealers and professional or sophisticated investors are permitted to view quotations in Expert Market securities.
(above per OTCMarkets)

Bid 0.00
Ask 0.00
https://ih.advfn.com/stock-market/USOTC/respirerx-pharmaceuticals-ce-RSPI/stock-price
https://www.otcmarkets.com/stock/RSPI/quote


You can buy or sell RSPI shares if you can find a broker willing to take the trade and are willing to do so without a quote.
I believe the B/A numbers you are seeing here are actually based on the latest trading activity and not actual offers to buy and sell.

jmo

Yeah I don't understand where the b/a is coming from with no centralized platform. I wonder if what is reported here is just individual brokers b/a and it could be completely different at another brokerage.

Regardless, the EM trading is ridiculous situation for pharma assets heading into clinical trials.

10K 0.0024
1,100,000 0.0011

What b/a?

There isn't any bid and ask lol
That's the effect of being on the Expert Market.

It is all bread crumbs in terms of volume on the EM.

They need to ink some small level of funding to get the filings current and convey a strategy with the assets going forward. Use a little bit of funds and a little effort into communication and presentation of the company and the pps will be back to where they left off. Get current and then provide updates of the assets: DOD phase 2, NIH grant phase 1, OSA clinicals/FDA status, etc. By the time they exit the EM and get the clinicals in motion on these assets the stock can be .05 +/-... Let clinical success and BP partnerships bring in the big whales and send it to a quarter....

Exactly, we need to get through $0.0025.

0,0025

Well they stated in 8-k to rectify situation they were seeking funding. The most logical explanation is they have been negotiating a significant funding deal and isolating the noise on this EM and pushing deals into 2025 had significant advantages.